Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1965 1
1968 1
1969 3
1970 1
1971 1
1972 3
1973 1
1975 2
1976 5
1977 2
1978 3
1979 3
1980 5
1981 3
1982 1
1983 1
1985 1
1989 1
1990 1
1992 1
2013 2
2014 2
2015 2
2016 3
2017 1
2018 3
2019 8
2020 3
2021 3
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma.
Roddie C, Lekakis LJ, Marzolini MAV, Ramakrishnan A, Zhang Y, Hu Y, Peddareddigari VGR, Khokhar N, Chen R, Basilico S, Raymond M, Vargas FA, Duffy K, Brugger W, O'Reilly MA, Wood L, Linch DC, Peggs KS, Bachier C, Budde EL, Lee Batlevi C, Bartlett N, Irvine D, Tholouli E, Osborne W, Ardeshna KM, Pule MA. Roddie C, et al. Among authors: budde el. Blood. 2023 May 18;141(20):2470-2482. doi: 10.1182/blood.2022018598. Blood. 2023. PMID: 36821767 Free PMC article.
WT1-mutated acute myeloid leukemia is sensitive to fludarabine-based chemotherapy and conditioning regimens.
Aribi A, Salhotra A, Afkhami M, Munteanu A, Ali H, Aldoss I, Otoukesh S, Al Malki MM, Sandhu KS, Koller P, Arslan S, Stewart F, Artz A, Curtin P, Ball B, O'Hearn J, Spielberger R, Smith E, Budde E, Nakamura R, Stein A, Forman S, Marcucci G, Becker PS, Pullarkat V. Aribi A, et al. Among authors: budde e. Leuk Lymphoma. 2023 Nov-Dec;64(11):1811-1821. doi: 10.1080/10428194.2023.2241096. Epub 2023 Aug 3. Leuk Lymphoma. 2023. PMID: 37533373
Chimeric Antigen Receptor T-Cell Therapy.
Ogba N, Arwood NM, Bartlett NL, Bloom M, Brown P, Brown C, Budde EL, Carlson R, Farnia S, Fry TJ, Garber M, Gardner RA, Gurschick L, Kropf P, Reitan JJ, Sauter C, Shah B, Shpall EJ, Rosen ST. Ogba N, et al. Among authors: budde el. J Natl Compr Canc Netw. 2018 Sep;16(9):1092-1106. doi: 10.6004/jnccn.2018.0073. J Natl Compr Canc Netw. 2018. PMID: 30181421
Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma.
Godfrey J, Mei M, Chen L, Song JY, Bedell V, Budde E, Armenian S, Puverel S, Nikolaenko L, Chen R, Daniels S, Kennedy N, Peters L, Rosen ST, Forman SJ, Popplewell LL, Kwak LW, Herrera AF. Godfrey J, et al. Among authors: budde e. Haematologica. 2024 Feb 1;109(2):533-542. doi: 10.3324/haematol.2023.283002. Haematologica. 2024. PMID: 37470137 Free PMC article. Clinical Trial.
Non-invasive fibrosis score for hepatitis delta.
Lutterkort GL, Wranke A, Yurdaydin C, Budde E, Westphal M, Lichtinghagen R, Stift J, Bremer B, Hardtke S, Keskin O, Idilman R, Koch A, Manns MP, Dienes HP, Wedemeyer H, Heidrich B. Lutterkort GL, et al. Among authors: budde e. Liver Int. 2017 Feb;37(2):196-204. doi: 10.1111/liv.13205. Epub 2016 Aug 10. Liver Int. 2017. PMID: 27428078
Xanthochromia of the skull bone associated with HbA1c.
Schäfer T, Klintschar M, Lichtinghagen R, Plagemann I, Smith A, Budde E, Hagemeier L. Schäfer T, et al. Among authors: budde e. Forensic Sci Int. 2016 Mar;260:54-58. doi: 10.1016/j.forsciint.2015.12.030. Epub 2016 Jan 7. Forensic Sci Int. 2016. PMID: 26799427
CD123 CAR T cells for the treatment of myelodysplastic syndrome.
Stevens BM, Zhang W, Pollyea DA, Winters A, Gutman J, Smith C, Budde E, Forman SJ, Jordan CT, Purev E. Stevens BM, et al. Among authors: budde e. Exp Hematol. 2019 Jun;74:52-63.e3. doi: 10.1016/j.exphem.2019.05.002. Epub 2019 May 25. Exp Hematol. 2019. PMID: 31136781 Free PMC article.
Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma.
Kumar A, Casulo C, Advani RH, Budde E, Barr PM, Batlevi CL, Caron P, Constine LS, Dandapani SV, Drill E, Drullinsky P, Friedberg JW, Grieve C, Hamilton A, Hamlin PA, Hoppe RT, Horwitz SM, Joseph A, Khan N, Laraque L, Matasar MJ, Moskowitz AJ, Noy A, Palomba ML, Schöder H, Straus DJ, Vemuri S, Yang J, Younes A, Zelenetz AD, Yahalom J, Moskowitz CH. Kumar A, et al. Among authors: budde e. J Clin Oncol. 2021 Jul 10;39(20):2257-2265. doi: 10.1200/JCO.21.00108. Epub 2021 Apr 28. J Clin Oncol. 2021. PMID: 33909449
64 results